Results of Grifols' AMBAR clinical trial published in Alzheimer's & Dementia

The Journal of The Alzheimer's Association

-- A group of independent experts from the influential peer-reviewed journal has evaluated Grifols' AMBAR results (Alzheimer Management by Albumin Replacement)

-- Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's

-- The publication reflects more than 15 years of Grifols' research and confirms the potential for plasma therapies to address high-prevalence diseases

BARCELONA, Spain, July 27, 2020 /PRNewswire/ -- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the prestigious peer-reviewed scientific journal, today has published the results of Grifols' AMBAR study. This clinical trial was designed to assess the effects of plasma protein replacement therapy in patients experiencing either mild or moderate stages of Alzheimer's disease (AD).

The findings of the AMBAR clinical trial demonstrate a delay in the cognitive and functional decline in AD patients when their plasma is replaced with albumin and immunoglobulin (plasma-derived proteins) following the process of plasma extraction, using the plasmapheresis technique. The results reveal a positive impact in reducing the progression of Alzheimer's symptoms in patients treated over a 14-month period compared to untreated patients.

According to Dr. Antonio Páez, Grifols' medical director of the AMBAR clinical program and one of the main authors of the article, "These findings are very encouraging. Their publication in one of the most influential journals in the field underscores the relevance of Grifols' research over the last 15 years and its innovative new approach in the fight against Alzheimer's."

The results of the clinical trial's primary endpoints were supported by those obtained in the most relevant secondary endpoints, in which similar effects were observed. In addition, the clinical trial has shown that plasma exchange is a perfectly feasible protocol in the patient population studied.

According to Eduardo Herrero, president of the Bioscience division industrial group of Grifols, "This publication leads the way on the future development of plasma protein replacement therapies. At Grifols, we continue our efforts to expand their possibilities so that thousands of patients can benefit."

The findings now published are the result of rigorous scientific research and reinforce the potential of plasma therapies to treat complex diseases.

Grifols will continue its research on the applications of plasma-derived treatments in parallel with its commitment to develop a therapy to treat Alzheimer's and other degenerative diseases.